Skip to main content
Future Journal of Pharmaceutical Sciences
Download PDF

In vitro antioxidant, anti-inflammatory, and anticancer activities of methanolic extract and its metabolites of whole plant Cardiospermum canescens Wall

Future Journal of Pharmaceutical Sciences volume 6, Article number: 11 (2020) Cite this article

Abstract

Background

Traditionally, the whole plant of Cardiospermum canescens has wide applications in the management of oxidative stress and inflammation in Africa and Asia. The present study investigated the antioxidant, anti-inflammatory, xanthine oxidase (XO) inhibitory, and anticancer activities of metabolites present in the crude methanolic extract of whole plant C. canescens (CCE).

Results

Chemical examination of CCE revealed the presence of six known compounds (1–6). From the results of in vitro studies, it can confirm that CCE exhibited notably inhibition of DPPH and superoxide free radicals, along with COX-1, COX-2, 5-LOX, and XO enzymes. Compounds 2 and 3 showed significant inhibition of DPPH and superoxide free radicals. Also, compound 2 exhibited good inhibition of COX-1 and COX-2 enzyme with IC50 of 87.0 and 88.0 μg/mL. Furthermore, CCE exhibited significant inhibition of 5-LOX and XO enzymes with IC50 of 42.5 and 56.0 μg/mL, respectively, while standard with IC50 of 42.5 and 56.0 μg/mL, respectively. Among the test series of cancer cell lines, compounds 2, 3, and CCE showed a significant percentage of cell growth lysis of DLD-1 with IC50 values of 52.5, 72.5, and 32.5 μg/mL, respectively. Besides, all the metabolites and CCE showed a very weak degree of specificity against NHME, indicates less toxicity to normal cells.

Conclusion

To conclude, the results of the present study indicated that the methanolic extract from the whole plant of C. canescens displayed antioxidant activity by inhibiting DPPH and superoxide free radicals; anti-inflammatory effects by regulating enzymes COX-1, COX-2, 5-LOX, and XO; and anticancer activity by inhibiting the growth of MCF-7, DLD-1, HeLa, and A549. These activities can link to natural active compounds 2 and 3. This study supports the traditional uses of the root of C. canescens. These data findings suggest that C. canescens can be a promising natural source of biological medicines for oxidative stress, inflammation, gout, and cancer.

Background

Cardiospermum is the sole genus of the tropical family Sapindaceae, which records in the flora of Africa and Asia. Cardiospermum genus comprises about 30 species across the globe; most of them are reported to be existing in India. Among these, Cardiospermum canescens is a climber, commonly termed as “Love in a puff” and “Balloon plant.” [1] In the folklore of India and some other Asian countries, the whole plant of Cardiospermum species has been used in the treatment of swelling and tumors. Especially, the tribes of Africa and Asia used the whole plant of Cardiospermum in the management of rheumatoid arthritis [1, 2]. Also, in the rural areas of Tamil Nadu state, India, the whole plant is used as a leafy vegetable for daily consumption [2, 3].

Biologically, the whole plant of C. canescens reported for arthritis, lumbago, neuropathy, fever, stiffness of limbs, piles, nervous disorders, neuropathy, diaphoretic, snake bites, laxative, diuretic, emmenagogue, and mucilaginous [4]. Earlier, a series of phytochemical constituents, namely flavonoids, triterpenoids, saponins, carbohydrates, proteins, alkaloids, and tannins was identified from C. canescens [4, 5]. To date, antioxidant, antibacterial, hepatoprotective effects, and cytotoxicity activities were investigated on C. canescens [1, 3, 5, 6]. Besides, no chemical investigation has attempted to evaluate the chemical constituents of C. canescens. So, the present research study mainly aimed to analyze the chemical composition of the crude methanolic extract of whole plant C. canescens (CCE) employing chromatography and to monitor antioxidant, xanthine oxidase (XO) inhibitory, anti-inflammatory, and anticancer activities of isolated metabolites and CCE.

Methods

Plant material

The whole plant of Cardiospermum canescens Wall (Family: Sapindaceae) was collected in Tirupathi Seshachalam hills, Tirupati, Andhra Pradesh, India, in February 2019. Dr. K. Madhava Chetty of Faculty of Sri Venkateswara University (SVU), Tirupati, Andhra Pradesh, India, has authenticated the sample and a voucher specimen with accession number PS-2019-225 which has been deposited at the Department of Botany, SVU, Tirupati, Andhra Pradesh, India.

Reagents

Diclofenac, 5-lipoxygenase (5-LO), trichloroacetic acid (TCA), xanthine, and xanthine oxidase (XO) were purchased from Sigma Aldrich (USA). Cyclooxygenase 1 and Cyclooxygenase 2 (COX-1 and COX-2; no. 560131) purchased from Cayman (USA). Other chemicals were of analytical grade.

Extraction and isolation of compounds from whole plant C. canescens

The whole plant C. canescens (1.0 kg) was dried and powdered and extracted thrice with methanol (96%) at 25 °C (3 times × 3 days/time). The obtained fractions were evaporated under vacuum to obtain a methanolic extract of C. canescens (CCE, 45 g, 4.5%w/w).

The CCE extract (50 g) was exposed to silica gel (#100-200) column chromatography (CC) through a step gradient of hexane/ethyl acetate solvent, which yielded five main fractions (FI–FV). FI (2 g) subjected to CC (#100-200) against n-hexane/ethyl acetate (step gradient) yielded 1 (110 mg) as a yellowish solid. By using CC (#100-200), FII (2.5 g) with dichloromethane/ethyl acetate solvent system (step gradient) obtained 2 (115 mg) as a pale yellow solid, and 3 (110 mg) as a white powder. Similarly, FIII (800 mg) yielded 4 (80 mg) as a grayish solid, FIV (1.0 g) yielded 5 (100 mg) as a greenish semi-solid, and FIV (1.2 g) yielded 6 (120 mg) as a pale brownish solid.

Antioxidant activity

DPPH assay

The metabolites (1–6) and CCE were subjected to 1,1-diphenyl-2-picrylhydrazyl (DPPH) assay [7] in triplicate. Known concentrations of the sample added 0.004% DPPH in methanol. After that, it was incubated at 37 °C for half an hour and recorded for absorbance at 517 nm against the blank using UV-visible spectrophotometry (Spectra MAX plus 384, USA).

Superoxide radical scavenging assay

The metabolites (1–6) and CCE were subjected to scavenging assay of superoxide [8] in triplicate. Known concentrations of the sample added 1 mL of a standardized solution containing 50 μM NBT + 73 μM NADH + 15 μM of PMS in phosphate buffer (pH 7.4) and incubated for 30 min. After that, absorbance was recorded at 562 nm against the blank.

In vitro assays of anti-inflammatory activity

Cyclooxygenase (COX-1 and COX-2) inhibitory assay

By COX inhibitor screening assay kit (Cayman Chemical Company, MI), metabolites (1–6), and CCE were estimated for inhibitory activities of COX [9]. Diclofenac and different concentrations of extracts were used as inhibitor sources. The prostaglandin 2α amount obtained from COX-1 and COX-2 employing substrate arachidonic acid was estimated by using the enzyme immunoassay (EIA) of the same kit. This inhibitory assay performed thrice and their IC50 values attained by analysis of linear regression.

5-Lipoxygenase inhibitory assay

The 5-lipoxygenase (5-LOX) activity [10] on linoleic acid was partly disrupted by using a series of metabolites (1–6) and CCE concentrations. By the end of the reaction time, the absorbances of reaction mixtures were determined at 234 nm and the IC50 was then calculated. This inhibitory assay was performed thrice with Quercetin as a standard.

Xanthine oxidase inhibitory activity assay

The XO inhibitory activity [11] determined according to a described method with slight modifications. Briefly, to 10 μl of 5 mM xanthine (substrate), 470 μl of sodium phosphate buffer of pH 8.0, 10 μl of the sample (metabolites (1–6) and CCE) was dissolved in DMSO, and 10 μl of enzyme XO was added and mixed in the well, then incubated for 5 min at 25 °C. Later, absorbance was noted at 295 nm. Allopurinol and DMSO were used as standard and control. This inhibitory assay was performed thrice, and their IC50 values were obtained by plotting concentration against respective percentage inhibition.

In vitro anticancer assay

Sulforhodamine B colorimetric assay

The in vitro anticancer activity of metabolites (1–6) and CCE was determined by Sulforhodamine B (SRB) assay [12] using four cancer cell lines—MCF-7 (Breast), DLD-1 (Colon), HeLa (Cervical), and A549 (Lung)—and one normal human cell line—normal human mammary epithelial (NHME) (provided by National Centre for Cell Science, Pune). All cell lines were maintained and sampling was prepared according to the procedures of Tatipamula et al. [12]. To 190 μL, screened ideal cell suspension was added to known concentrations of the sample and incubated for 3 h at 37 °C with 90% relative humidity and in the presence of 5% CO2. After that, 100 μL cold TCA was added and again incubate for 1 h at 4 °C. Then, the entire 96-well plate is washed and air-dried at 25 °C. Then, add 100 μL SRB solution (0.057%); after 30 min, rinse with 1% CH3COOH and add 200 μL Tris base (10 mM, pH 10.5) solution; and shake for 5 min; absorbance was measured at 510 nm against a blank (contains the only medium).

Statistical analysis

All in vitro assay test results were note as mean ± SD. A one-way analysis of variance (ANOVA) was followed by a t test with p < 0.05 measured to be statistically significant.

Results

Chemistry

For the first time, six known compounds (1–6) were identified from the methanolic extract of C. canescens (CCE) utilizing chromatographic methods and analyses of spectral data namely 1H NMR, MS, IR, and 13C NMR (see supplemental file) and correlated with those reported in the literature (Fig. 1).

Fig. 1
figure 1

Known metabolites identified from methanolic extract of Cardiospermum canescens

Full size image

Compound 1 [(1R,9S,Z)-4,11,11-trimethyl-8-methylenebicyclo[7.2.0]undec-4-ene] was obtained as a yellowish solid with Rf value of 0.8 in hexane and ethyl acetate (4:1). Mol. formula: C15H24. Purity: above 95% pure (based on TLC and NMR observations). 1H NMR (400 MHz, CDCl3): 0.986 (s, 6H), 1.083–1.127 (m, 1H), 1.334–1.378 (m, 1H), 1.685–1.687 (m, 4H), 1.955–1.993 (m, 3H), 1.993–2.157 (m, 4H), 2.510–2.520 (d, 1H, J = 4 Hz), 2.922 (s, 1H), 4.605–4.609 (d, 1H, J = 0.8 Hz), 4.855–4.857 (d, 1H, J = 0.8 Hz), 5.162–5.189 (m, 1H); 13C NMR (400 MHz, CDCl3): 22.21 (C-12), 27.42 (C-5), 29.29 (C-14/15), 30.86 (C-1), 36.82 (C-9/10), 40.13 (C-4), 42.29 (C-11), 51.61 (C-7), 54.52 (C-6), 114.13 (C-13), 126.83 (C-2), 137.31 (C-3), 154.90 (C-8). ESI-MS (positive mode) m/z: 205 [M + H+], calcd. m/z for C15H24: 204.19 [M]. FT-IR (in KBR): 757.67, 830.97, 1037.70, 1088.51, 1129.48, 1160.81, 1239.96, 1342.80, 1420.75, 1455.71, 1503.45, 1581.58, 1619.37, 1657.04, 2864.85, 2926.91, 2958.57 cm−1.

Compound 2 [(1S,5R,9R)-10,10-dimethyl-2,6-dimethylenebicyclo[7.2.0]undecan-5-ol] was obtained as a pale yellow solid with Rf value of 0.4 in chloroform and ethyl acetate (3:7). Mol. formula: C15H24O. Purity: above 95% pure (based on TLC and NMR observations). 1H NMR (400 MHz, CDCl3): 0.944 (s, 6H), 1.044–1.082 (m, 1H), 1.295–1.320 (m, 1H), 1.320–1.333 (m, 1H), 1.532–1.543 (m, 2H), 1.613–1.635 (m, 1H), 1.783–1.882 (m, 1H), 1.902–1.926 (m, 1H), 2.013–2.038 (m, 2H), 2.116–2.141 (m, 2H), 2.444–2.504 (m, 1H), 2.992 (s, 1H, -OH), 4.563–4.567 (dd, 2H, J = 0.8 Hz), 4.813–4.817 (dd, 2H, J = 0.8 Hz); 13C NMR (400 MHz, CDCl3): 22.80 (C-4), 24.05 (C-14/15), 28.98 (C-3), 29.56 (C-8), 30.03 (C-9), 31.59 (C-10), 37.06 (C-11), 46.37 (C-6), 49.29 (C-5), 72.64 (C-1), 107.12 (C-12), 108.74 (C-13), 147.5 (C-2), 147.87 (C-7). ESI-MS (positive mode) m/z: 221 [M + H+], calcd. m/z for C15H24O: 220.18 [M]. FT-IR (in KBR): 758.70, 1462.79, 28.55.53, 2921.95 cm−1.

Compound 3 [(1R,4R,10S)-4,12,12-trimethyl-9-methylene-5-oxatricyclo[8.2.0.04,6]dodecane] was obtained as a white powder with Rf value of 0.6 in hexane and ethyl acetate (1:1). Mol. formula: C15H24O. Purity: above 95% pure (based on TLC and NMR observations). 1H NMR (400 MHz, CDCl3): 0.960 (s, 6H), 1.160 (s, 3H), 1.239–1.279 (m, 4H), 1.389–1.630 (m, 2H), 1.647–1.691 (m, 2H), 1.898–1.942 (m, 1H), 2.054–2.175 (m, 2H), 2.190–2.205 (m, 1H), 2.461–2.519 (m, 1H), 4.829–4.831 (dd, 2H, J = 0.8 Hz); 13C NMR (400 MHz, CDCl3): 22.87 (C-12), 27.28 (C-4), 32.01 (C-9), 32.22 (C-14/15), 38.07 (C-8), 39.75 (C-10), 40.40 (C-3), 45.22 (C-11), 54.54 (C-6), 59.44 (C-5), 65.15 (C-2), 67.48 (C-1), 116.90 (C-13), 156.03 (C-7). ESI-MS (positive mode) m/z: 221 [M + H+], calcd. m/z for C15H24O: 220.18 [M]. FT-IR (in KBR): 757.43, 1164.22, 1243.88, 1280.23, 1371.49, 1462.62, 1625.60, 2855.31, 2920.71 cm−1.

Compound 4 [(3S,3aS,6R,8aS)-3,7,7-trimethyl-8-methyleneoctahydro-1H-3a,6-methanoazulene] was obtained as a grayish solid with Rf value of 0.4 in hexane and ethyl acetate (1:1). Mol. formula: C15H24. Purity: above 95% pure (based on TLC and NMR observations). 1H NMR (400 MHz, CDCl3): 0.893–0.918 (m, 1H), 1.053–1.066 (d, 3H, J = 5.2 Hz), 1.144–1.169 (m, 1H), 1.292–1.298 (m, 1H), 1.386 (s, 6H), 1.433–1.438 (m, 2H), 1.486–1.515 (m, 1H), 1.543–1.574 (m, 2H), 1.568–1.574 (m, 1H), 1.660–1.687 (m, 2H), 2.071–2.106 (t, 2H, J = 6.8, 7.2 Hz), 4.975–4.980 (dd, 2H, J = 0.8 Hz); 13C NMR (400 MHz, CDCl3): 12.17 (C-15), 21.42 (C-9), 23.62 (C-13/14), 23.77 (C-4), 28.97 (C-10), 34.26 (C-5), 35.55 (C-2), 38.14 (C-8/11), 43.31 (C-7), 43.50 (C-3), 52.69 (C-6), 101.50 (C-12), 156.57 (C-1). ESI-MS (positive mode) m/z: 205 [M + H+], calcd. m/z for C15H24: 204.19 [M]. FT-IR (in KBR): 758.59, 1466.21, 2853.30, 2919.84 cm−1.

Compound 5 [(1R,2S,6S,7S,8S)-8-isopropyl-1,3-dimethyltricyclo[4.4.0.02,7]dec-3-ene] was obtained as a greenish semi-solid with Rf value of 0.6 in chloroform and ethyl acetate (3:7). Mol. formula: C15H24. Purity: above 95% pure (based on TLC and NMR observations). 1H NMR (400 MHz, CDCl3): 1.044 (s, 3H), 1.057 (s, 3H), 1.061 (s, 3H), 1.215–1.318 (m, 1H), 1.326–1.331 (m, 1H), 1.409–1.434 (m, 2H), 1.488–1.512 (m, 1H), 1.606–1.755 (m, 2H), 1.811–1.871 (m, 2H), 1.912 (s, 1H), 1.913 (s, 3H), 2.050–2.093 (m, 1H), 5.529 (t, 1H, J = 0.8 Hz); 13C NMR (400 MHz, CDCl3): 22.26 (C-5/13/14), 25.62 (C-15), 26.07 (C-11), 30.44 (C-12), 33.80 (C-9), 38.10 (C-6), 39.41 (C-7), 44.84 (C-8), 46.31 (C-4), 47.30 (C-3), 49.31 (C-2), 120.87 (C-10), 143.44 (C-1). ESI-MS (positive mode) m/z: 205 [M + H+], calcd. m/z for C15H24: 204.19 [M]. FT-IR (in KBR): 757.07, 831.97, 1036.44, 1089.60, 1130.24, 1160.95, 1258.86, 1344.88, 1419.78, 1455.32, 1505.34, 1580.19, 1621.23, 1653.08, 2875.04, 2962.67 cm−1.

Compound 6 [(3aR,6R,7S,8aS)-6,8,8-trimethyl-3-methyleneoctahydro-1H-3a,7-methanoazulene] was obtained as a pale brownish solid with Rf value of 0.4 in chloroform and ethyl acetate (1:1). Mol. formula: C15H24. Purity: above 95% pure (based on TLC and NMR observations). 1H NMR (400 MHz, CDCl3): 0.880–0.893 (s, 3H, J = 5.2 Hz), 0.937 (s, 6H), 1.061–1.069 (m, 2H), 1.111–1.166 (m, 1H), 1.175–1.180 (m, 2H), 1.185–1.189 (m, 1H), 1.362–1.368 (m, 1H), 1.387–1.429 (m, 4H), 2.054–2.092 (d, 2H, J = 15.2 Hz), 4.587–4.595 (t, 1H, J = 0.8, 2.4 Hz); 13C NMR (400 MHz, CDCl3): 22.03 (C-13), 26.08 (C-14/15), 29.07 (C-11), 30.59 (C-3), 32.88 (C-4), 35.35 (C-10), 35.44 (C-5), 37.96 (C-8), 46.59 (C-1), 52.74 (C-6), 56.18 (C-2), 60.45 (C-7), 100.53 (C-12), 157.13 (C-9). ESI-MS (positive mode) m/z: 205 [M + H+], calcd. m/z for C15H24: 204.19 [M]. FT-IR (in KBR): 699.83, 805.16, 849.70, 1163.13, 1205.87, 1268.76, 1321.28, 1447.21, 1499.94, 1625.06, 2857.43, 2921.21, 3356.81 cm−1.

Antioxidant activity

Initially, CCE was exposed to an initial test against DPPH [7] and superoxide [8] assays, and its IC50 values were found to be 60.0 and 62.5 μg/mL, respectively, whereas standard (ascorbic acid) value was 27.8 and 32.1 μg/mL, respectively. Based on the preliminary antioxidant analysis of CCE, we subjected its metabolites (1–6) for antioxidant activity. Among all the tested compounds, only compounds 2 and 3 showed moderate inhibition of DPPH and superoxide free radicals. The concentration of 2 needed for 50% inhibition of DPPH and superoxide free radicals was found to be 169.0 and 180.0 μg/mL, respectively, while 3 with 285.0 and 230.0 μg/mL, respectively (Fig. 2).

Fig. 2
figure 2

IC50 values of isolated metabolites and methanolic extract of Cardiospermum canescens (CCE) against DPPH and superoxide free radicals. DPPH, 1,1-diphenyl-2-picrylhydrazyl; n = 3, mean ± SD values. Statistical analysis: one-way ANOVA followed by t test. *Statistically significant (p < 0.05) between free radicals treatment with compounds and extract

Full size image

Anti-inflammatory activity

The anti-inflammatory effect of metabolites (1–6) and CCE were evaluated based on their inhibitory activities against COX-1 and 2 [9], 5-LOX [10] and XO [11] enzymes, initially at 100 μg/mL concentration. During initially screening, CCE showed better inhibitor profile against COX-1, COX-2, 5-LOX, and XO enzymes with 72.50 ± 3.44, 80.80 ± 4.30, 70.67 ± 4.57, and 75.90 ± 4.25 %enzyme inhibition, respectively. Besides, among the metabolites, only compound 2 at 100 μg/mL concentration displayed significant inhibitory profile on particularly COX-1 and 2 enzymes with 58.17 ± 3.67 and 56.50 ± 4.50 %enzyme inhibition, respectively. Hence, the active samples, i.e., compound 2 and CCE, are further examined at 25, 50, 75, and 100 μg/mL concentrations with standard drugs (indomethacin, diclofenac, and allopurinol) at 2.5, 5.0, 7.5, and 10.0 μg/mL concentrations. From the obtained results, IC50 values calculated by plotting concentration against percentage enzyme inhibition.

The 50% COX-1 enzyme inhibitory concentration required for compound 2 and CCE was found to be 87.0 and 45.0 μg/mL, respectively, whereas indomethacin with 4.2 μg/mL (Fig. 3a). Similarly, the IC50 values of compound 2 and CCE on COX-2 were found to be 88.0 and 63.1 μg/mL, respectively, while indomethacin with 4.2 μg/mL (Fig. 3b). The concentration needed for 50% inhibition of 5-LOX and XO enzymes of CCE was determined to be 42.5 and 56.0 μg/mL, respectively, whereas standard drugs (diclofenac and allopurinol) with 2.7 and 2.6 μg/mL, (Fig. 3c, d).

Fig. 3
figure 3

Percentage enzyme inhibition and IC50 values of isolated metabolites and methanolic extract of Cardiospermum canescens (CCE) against COX-1, COX-2, 5-LOX, and XO enzymes. n = 3, mean ± SD values; Statistical analysis: one-way ANOVA followed by t test. *Statistically significant (p < 0.05) between enzymes treatment with compounds and extract

Full size image

Anticancer activity

Firstly, all the isolated metabolites (1–6) and CCE tested against MCF-7 (breast), DLD-1 (colon), HeLa (cervical), A549 (lung), and normal human mammary epithelial (NHME) cell lines at 100 μg/mL concentration. From the primary screening of SRB assay [12], it noticed that CCE showed a prominent degree of specificity against the tested series of cancer cell lines. At 100 μg/mL concentration, CCE potently inhibited the growth of DLD-1 and A549 with 81.71 ± 8.53 and 75.26 ± 8.55 %cell death, respectively, than standard drug doxorubicin (10 μg/mL) with 76.17 ± 7.71 and 69.54 ± 5.10 %cell death. Besides, metabolite 2 showed a significant degree of specificity against all the tested panel of cancer cell lines, while compound 3 against only DLD-1 and A549 and compound 1 against only A549.

Secondly, the samples showed above 50% of cell death, examined for further analysis at 25, 50, 75, and 100 μg/mL concentrations with the standard drug (doxorubicin) at 2.5, 5.0, 7.5, and 10.0 μg/mL concentrations. IC50 values calculated by plotting concentration against percentage cell growth inhibition. The IC50 values of 2 and CCE on MCF-7 were found to be 82.0 and 61.5 μg/mL, respectively, whereas doxorubicin with 3.2 μg/mL (Fig. 4a). The concentration of 2, 3, and CCE needed for 50% cell death of DLD-1 was found to be 52.5, 72.5, and 32.5 μg/mL, respectively, while doxorubicin with 4.2 μg/mL (Fig. 4b). From the results of SRB assay on HeLa, the IC50 values of 2 and CCE were found to be 96.0 and 78.0 μg/mL, respectively, whereas doxorubicin with 3.8 μg/mL (Fig. 4c). Similarly, the concentration needed for 50% cell death of A549 of 1, 2, 3, and CCE determined to be 99.5, 88.0, 76.0, and 56.5 μg/mL, respectively, while doxorubicin with 3.8 μg/mL (Fig. 4d). Besides, all the isolated compounds (1–6) and CCE showed a very mild degree of specificity against NHME which indicates that the samples are non-toxic to normal human cells.

Fig. 4.
figure 4

Percentage growth inhibition and IC50 values of isolated metabolites and methanolic extract of Cardiospermum canescens (CCE) against MCF-7, DLD-1, HeLa, and A549. MCF-7, breast cancer cell line; DLD-1, colon cancer cell line; HeLa, cervical cancer cell line; A549, lung cancer cell line; n = 3, mean ± SD values. Statistical analysis: one-way ANOVA followed by t test. *Statistically significant (p < 0.05) between cell lines treatment with compounds and extract

Full size image

Discussion

In the present study, six known secondary metabolites (1–6) were isolated from the methanolic extract of whole plant C. canescens (CCE). This identification provides new information on the phytochemical profile of C. canescens. Also, the biological profile of C. canescens justifies its natural aptitude to act against free radicals, inflammation, and cancer. From the DPPH and superoxide free radical assay, it observed that CCE inhibits them prominently. In the deep enzymatic analysis of anti-inflammation proved that the methanolic extract of whole plant C. canescens has potent inhibition of COX-1 and 2, 5-LOX, and XO enzymes. This observation helps to investigate the anticancer ability of C. canescens, and the outcomes of SRB assay showed that CCE has a significant degree of specificity against MCF-7, DLD-1, HeLa, and A549.

In general, inflammatory activity was caused by an elevated level of prostaglandins and leukotrienes in the body. Cyclooxygenase (COX-1 and 2) and 5-lipoxygenase (5-LOX) enzymes are responsible for the production of prostaglandins and leukotrienes, respectively. Hence, inhibition of COX-1 and 2 by anti-inflammatory drugs such as NSAIDs decrease the production of the prostaglandins, ultimately resulting in the reduction of inflammation, as well as pain [13,14,15]. Nevertheless, inhibition of particularly prostaglandins can cause activation of 5-LOX pathway alternative, which results in the elevation of pro-inflammatory and gastro-toxic leukotrienes production. Therefore, drugs that inhibit both COX and 5-LOX (dual inhibitors) reduce leukotrienes and prostaglandin production and completely inhibit inflammation. Also, by using dual inhibitors, the adverse effects on the cardiovascular system caused by selective COX-2 inhibitors (coxibs) will be reduced [16,17,18,19,20]. The results of the present study showed that CCE acted as a dual inhibitor and effectively inhibited both COX and 5-LOX enzymes, whereas compound 2 prominently inhibit particularly COX-1 enzyme.

Generally, uric acid formed from purines xanthine and purines hypoxanthine in the presence of an enzyme called xanthine oxidase (XO). Excess deposition of uric acid in the joints of the human body leads to severe joint pains, which is well known as gout (painful inflammation) [21, 22]. Furthermore, XO is a good biological source for oxygen-containing free radicals that damage living tissues and cause-related inflammatory diseases like aging, cancer, and atherosclerosis. Hence, XO inhibitors play a vital role in diagnosis, not only gout but also related inflammatory diseases [23,24,25]. This study suggests that only CCE possesses XO inhibitory activity that might be helpful in the management of gout and other inflammatory-related diseases.

Many scientists reported that chronic inflammation is the key causative factor in various types of cancers. Usually, the longer the existence of the inflammation, the greater the risk of cancer. In general, chronic exposure to inflammatory mediators, which include free radicals, cytokines, COX-1, COX-2, and 5-LOX, leads to a sharp rise in mutagenesis, cell proliferation, and oncogene activation eventually leading to the proliferation of cells which lost control over normal growth [26,27,28,29,30,31]. So, as metabolites and CCE showed good anti-inflammatory properties, we further investigated their anticancer abilities using the SRB assay. From the outcomes, it is justified that compound 2, 3, and CCE have an ability to lysis the cells of MCF-7, DLD-1, HeLa, and A549. Also, all the metabolites and CCE are less toxic towards the human cell lines.

In the folklore, the whole plant of C. canescens has applications in managing acute arthritis, rheumatism, inflammation, and cancer in India. The present study scientifically justifies the uses of the C. canescens as an antioxidant, anti-inflammatory, and anticancer agent in traditional medicine. The major phytoconstituents in CCE were identified as 1–6. Thus, these active constituents might be responsible for the biological activities of CCE.

Conclusion

To conclude, the results of the present study indicated that the methanolic extract from the whole plant of C. canescens displayed antioxidant activity by inhibiting DPPH and superoxide free radicals; anti-inflammatory effects by regulating enzymes COX-1, COX-2, 5-LOX, and XO; and anticancer activity by inhibiting the growth of MCF-7, DLD-1, HeLa and A549. The key metabolite responsible for in vitro activities were claimed to be compound 2 and 3. The results provide evidence that supports the traditional uses of the whole plant of C. canescens. Also, these findings suggest that the plant of C. canescens can take an account as a good natural source of remedial medicine for alleviating pain and cancer. However, an in-deep chemical and biological examination is further required to use the natural source (i.e., C. canescens) in the management of oxidative stress conditions, inflammation, gout, and cancer.

Availability of data and materials

All data and material are available upon request.

Abbreviations

5-LOX:

5-Lipoxygenase

A549:

Lung cancer cell line

CC:

Column chromatography

CCE:

Crude methanolic extract of whole plant Cardiospermum canescens

COX-1:

Cyclooxygenase 1

COX-2:

Cyclooxygenase 2

DLD-1:

Colon cancer cell line

DMSO:

Dimethyl sulfoxide

DPPH:

1,1-Diphenyl-2-picrylhydrazyl

HeLa:

Cervical cancer cell line

MCF-7:

Breast cancer cell line

NHME:

Normal human mammary epithelial

NMR:

Nuclear magnetic resonance

TCA:

Trichloroacetic acid

TLC:

Thin-layer chromatography

XO:

Xanthine oxidase

References

  1. Udhayasankar MR, Danya U, Punitha D, Arumugasamy K (2013) In vitro cytotoxic activity of methanolic extract of Cardiospermum canescens Wall.(Sapindaceae). Research in Pharmacy 3:1–5

    Google Scholar 

  2. Shivamanjunath MP, Sreenath KP (2013) Phytochemical studies on Cardiospermum canescens Wall. American International Journal of Research in Formal, Applied and Natural Sciences 3:61–65

    Google Scholar 

  3. Udhayasankar MR, Danya U, Punitha D, Arumugasamy K, Shalimol A (2013) In vitro anti-bacterial activity of methanolic extract of Cardiospermum canescens-a wild medicinal plant. Int J Herb Med 1:73–75

    Google Scholar 

  4. Silva FL, Moreno PR, Braz-Filho R, Tavares JF, Barbosa-Filho JM (2014) Chemical constituents of Cardiospermum corindum L. and their distribution in Sapindaceae. Biochem Syst Ecol 57:137–140 https://doi.org/10.1016/j.bse.2014.07.021

    Article  CAS  Google Scholar 

  5. Udhayasankar MR, Danya U, Punitha D, Arumugasamy K (2013) Antioxidant activity of Cardiospermum canescens Wall. (Sapindaceae)-a wild edible plant from western Ghats. Int J Pharm Pharm Sci 5:322–324

    Google Scholar 

  6. Manda RM, Parshaboina VK, Mudideni R, Mydaraboina K (2013) Hepatoprotective effect of Cardiospermum canescens on carbon tetrachloride induced hepatotoxicity in albino rats. Int J Pharm Res Sci 3:64–71

    Google Scholar 

  7. Tatipamula VB, Vedula GS, Sastry AV (2019) Chemical and pharmacological evaluation of manglicolous lichen Roccella montagnei Bel em. DD Awasthi. Future. Journal of Pharmaceutical Sciences 5:8 https://doi.org/10.1186/s43094-019-0009-6

    Google Scholar 

  8. Tatipamula VB, Killari KN, Ketha A, Sastry VG (2017) Taxithelium napalense acts against free radicals and diabetes mellitus. Bangladesh J Pharmacol 12:197–203 https://doi.org/10.3329/bjp.v12i2.31764

    Article  Google Scholar 

  9. Selvam C, Jachak SM (2004) A cyclooxygenase (COX) inhibitory biflavonoid from the seeds of Semecarpus anacardium. J Ethnopharmacol 95:209–212 https://doi.org/10.1016/j.jep.2004.07.026

    Article  CAS  Google Scholar 

  10. Lee EJ, Kim JS, Kim HP, Lee JH, Kang SS (2010) Phenolic constituents from the flower buds of Lonicera japonica and their 5-lipoxygenase inhibitory activities. Food Chem 120:134–139 https://doi.org/10.1016/j.foodchem.2009.09.088

    Article  CAS  Google Scholar 

  11. Owen PL, Johns T (1999) Xanthine oxidase inhibitory activity of northeastern North American plant remedies used for gout. J Ethnopharmacol 64:149-160. https://doi.org/10.1016/S0378-8741(98)00119-6

  12. Tatipamula VB, Killari KN, Prasad K, Rao GS, Talluri MR, Vantaku S, Bilakanti D, Srilakshmi N (2019) Cytotoxicity studies of the chemical constituents from marine algae Chara baltica. Indian J Pharm Sci 81:815–823 https://doi.org/10.36468/pharmaceutical-sciences.575

    Google Scholar 

  13. Charlier C, Michaux C (2003) Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur J Med Chem 38:645-659. https://doi.org/10.1016/S0223-5234(03)00115-6

  14. Canali R, Comitato R, Schonlau F, Virgili F (2009) The anti-inflammatory pharmacology of Pycnogenol® in humans involves COX-2 and 5-LOX mRNA expression in leukocytes. Int Immunopharmacol 9:1145–1149 https://doi.org/10.1016/j.intimp.2009.06.001

    Article  CAS  Google Scholar 

  15. Fiorucci S, Meli R, Bucci M, Cirino G (2001) Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy?. Biochem Pharmacol 62:1433-1438. https://doi.org/10.1016/S0006-2952(01)00747-X

  16. Mazumder S, De R, Sarkar S, Siddiqui AA, Saha SJ, Banerjee C, Iqbal MS, Nag S, Debsharma S, Bandyopadhyay U (2016) Selective scavenging of intra-mitochondrial superoxide corrects diclofenac-induced mitochondrial dysfunction and gastric injury: a novel gastroprotective mechanism independent of gastric acid suppression. Biochem Pharmacol 121:33–51 https://doi.org/10.1016/j.bcp.2016.09.027

    Article  CAS  Google Scholar 

  17. Gilroy DW, Tomlinson A, Willoughby DA (1998) Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation. Eur J Pharmacol 355:211-217. https://doi.org/10.1016/S0014-2999(98)00508-1

  18. Jäggi R, Würgler U, Grandjean F, Weiser M (2004) Dual inhibition of 5-lipoxygenase/cyclooxygenase by a reconstituted homeopathic remedy; possible explanation for clinical efficacy and favourable gastrointestinal tolerability. Inflamm Res 53:150–157 https://doi.org/10.1007/s00011-003-1236-y

    Article  Google Scholar 

  19. Martel-Pelletier J, Lajeunesse D, Reboul P, Pelletier JP (2003) Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 62:501–509 https://doi.org/10.1136/ard.62.6.501

    Article  CAS  Google Scholar 

  20. Dyer RD, Connor DT (1997) Dual inhibitors of prostaglandin and leukotriene biosynthesis. Curr Pharm Des 3:463–472

    CAS  Google Scholar 

  21. Booth VH (1938) The specificity of xanthine oxidase. Biochem J 32:494 https://dx.doi.org/10.1042%2Fbj0320494

    Article  CAS  Google Scholar 

  22. Ragab G, Elshahaly M, Bardin T (2017) Gout: An old disease in new perspective–a review. J Adv Res 8:495–511 https://doi.org/10.1016/j.jare.2017.04.008

    Article  CAS  Google Scholar 

  23. Denoble AE, Huffman KM, Stabler TV, Kelly SJ, Hershfield MS, McDaniel GE, Coleman RE, Kraus VB (2011) Uric acid is a danger signal of increasing risk for osteoarthritis through inflammasome activation. Proc Natl Acad Sci USA 108:2088–2093 https://doi.org/10.1073/pnas.1012743108

    Article  CAS  Google Scholar 

  24. Pétrilli V, Martinon F (2007) The inflammasome, autoinflammatory diseases, and gout. Joint Bone Spine 74:571–576 https://doi.org/10.1016/j.jbspin.2007.04.004

    Article  Google Scholar 

  25. Edwards NL (2008) Gout. In: Primer on the rheumatic diseases. Springer, New York, pp 241–262

    Chapter  Google Scholar 

  26. Liede A, Karlan BY, Narod SA (2004) Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 22:735–742

    Article  CAS  Google Scholar 

  27. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, Broeks A, Cox A, Fasching PA (2011) Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the breast cancer association consortium studies. J Natl Cancer Inst 103:250–263 https://doi.org/10.1093/jnci/djq526

    Article  Google Scholar 

  28. Ferrandina G, Ranelletti FO, Lauriola L, Fanfani F, Legge F, Mottolese M, Nicotra MR, Natali PG, Zakut VH, Scambia G (2002) Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer. Gynecol Oncol 85:305–310 https://doi.org/10.1006/gyno.2002.6620

    Article  CAS  Google Scholar 

  29. Crofford LJ (1997) COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol 49:15–19

    CAS  Google Scholar 

  30. Ye YN, Wu WK, Shin VY, Bruce IC, Wong BC, Cho CH (2005) Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis 26:827–834 https://doi.org/10.1093/carcin/bgi012

    Article  CAS  Google Scholar 

  31. Yang HJ, Youn H, Seong KM, Yun YJ, Kim W, Kim YH, Lee JY, Kim CS, Jin YW, Youn B (2011) Psoralidin, a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation. Biochem Pharmacol 82:524–534 https://doi.org/10.1016/j.bcp.2011.05.027

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors are thankful to the authorities of the AU College of Pharmaceutical Sciences, Andhra University, for providing the necessary facilities to complete the present work.

Plant source

The whole plant of Cardiospermum canescens Wall (Family: Sapindaceae) was collected in Tirupathi Seshachalam hills, Tirupati, Andhra Pradesh, India, in February 2019. Dr. K. Madhava Chetty of Faculty of Sri Venkateswara University (SVU), Tirupati, Andhra Pradesh, India, has authenticated the sample and a voucher specimen with accession number PS-2019-225 was deposited at the Department of Botany, SVU, Tirupati, Andhra Pradesh, India.

Studies involving plants

As per the local and national guidelines and legislation and the required or appropriate permissions and/or licenses for the study.

Funding

No funding was received.

Author information

Authors and Affiliations

  1. Pharmaceutical Chemistry Department, AU College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, 03, India

    Alekhya Ketha & Girija Sastry Vedula

  2. Pharmacology Department, MR College of Pharmacy, Vizianagaram, 02, India

    A. V. S. Sastry

Authors
  1. Alekhya Ketha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Girija Sastry Vedula
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. V. S. Sastry
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AK: Research scholar who carried isolation and biological evaluations and was a major contributor in writing the manuscript. GSV: Supervisor who guided in isolation and characterization of the secondary metabolites. AVSS: Professor in pharmacology who proposed and monitored the pharmacological studies. All authors have read and approved the manuscript.

Corresponding author

Correspondence to Alekhya Ketha.

Ethics declarations

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

No conflict of interest between any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Additional file 1: Figure S1.

1H NMR (400 MHz, CDCl3) of compound 1. Figure S2. 13C NMR (400 MHz, CDCl3) of compound 1. Figure S3. ESI-MS (positive mode) of compound 1. Figure S4. FT-IR of compound 1. Figure S5. 1H NMR (400 MHz, CDCl3) of compound 2. Figure S6. 13C NMR (400 MHz, CDCl3) of compound 2. Figure S7. ESI-MS (positive mode) of compound 2. Figure S8. FT-IR of compound 2. Figure S9. 1H NMR (400 MHz, CDCl3) of compound 3. Figure S10. 13C NMR (400 MHz, CDCl3) of compound 3. Figure S11. ESI-MS (positive mode) of compound 3. Figure S12. FT-IR of compound 3. Figure S13. 1H NMR (400 MHz, CDCl3) of compound 4. Figure S14. 13C NMR (400 MHz, CDCl3) of compound 4. Figure S15. ESI-MS (positive mode) of compound 4. Figure S16. FT-IR of compound 4. Figure S17. 1H NMR (400 MHz, CDCl3) of compound 5. Figure S18. 13C NMR (400 MHz, CDCl3) of compound 5. Figure S19. ESI-MS (positive mode) of compound 5. Figure S20. FT-IR of compound 5. Figure S21. 1H NMR (400 MHz, CDCl3) of compound 6. Figure S22. 13C NMR (400 MHz, CDCl3) of compound 6. Figure S23. ESI-MS (positive mode) of compound 6. Figure S24. FT-IR of compound 6. Table S1. Percentage inhibition and IC50 values of 1-6 and CCE against DPPH and superoxide free radicals. Table S2. Percentage inhibition and IC50 values of 1-6 and CCE against Cyclooxygenase (COX-1 & 2), 5-lipoxygenase (5-LOX) and Xanthine oxidase (XO) enzymes. Table S3. Percentage growth inhibition of 1-6 and CCE on four different cancer cell lines and one normal human cell line.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ketha, A., Vedula, G.S. & Sastry, A.V.S. In vitro antioxidant, anti-inflammatory, and anticancer activities of methanolic extract and its metabolites of whole plant Cardiospermum canescens Wall. Futur J Pharm Sci 6, 11 (2020). https://doi.org/10.1186/s43094-020-00028-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s43094-020-00028-y

Keywords